Hot Features
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unr... Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.21 | -14.6853146853 | 1.43 | 1.43 | 1.22 | 133680 | 1.29055213 | CS |
| 4 | -0.7 | -36.4583333333 | 1.92 | 2.12 | 1.22 | 127440 | 1.64231646 | CS |
| 12 | -1.04 | -46.017699115 | 2.26 | 2.46 | 1.22 | 214082 | 1.85283571 | CS |
| 26 | -1.93 | -61.2698412698 | 3.15 | 3.23 | 1.22 | 151916 | 2.10905392 | CS |
| 52 | -10.08 | -89.203539823 | 11.3 | 12.23 | 1.22 | 134929 | 4.35470919 | CS |
| 156 | -0.16 | -11.5942028986 | 1.38 | 12.23 | 0.17 | 1746705 | 4.12414996 | CS |
| 260 | -12.59 | -91.1658218682 | 13.81 | 41 | 0.17 | 1123798 | 4.55716049 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.